Elite Pharmaceuticals, Inc. (ELTP)

Every figure this model derived for ELTP, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,516,386 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 39,415,579 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2026-06-30
current assets 114,487,702 AssetsCurrent 2026-06-30
current liabilities 30,441,614 LiabilitiesCurrent 2026-06-30
equity 104,826,056 StockholdersEquity 2026-06-30
interest expense 109,733 InterestExpenseDebt 2026-06-30
ocf 19,042,069 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 141,014,305 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 152,654 AllocatedShareBasedCompensationExpense 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ELTP on one particular measure came for.

RatioValue
cash operating margin25.63
current ratio3.76
current ratio reported3.76
deferred revenue growth-83.33
dilution pct6.56
ebit cagr99.96
ebit yoy-6.66
fcf margin12.43
growth cv0.58
interest cover318.43
operating margin24.78
owner earnings margin12.32
revenue growth33.72
revenue growth per share25.49
roic41.48
rule of 4058.5
sbc pct revenue0.11

What to be careful about

What this model itself distrusts about ELTP's figures. Written by the derivation as it ran, not added afterwards.